Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Harvard Business School
Boehringer Ingelheim
Dow
Moodys
AstraZeneca
McKinsey

Last Updated: December 5, 2019

DrugPatentWatch Database Preview

Patent: 7,501,430

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 7,501,430
Title:RAF inhibitors and their uses
Abstract: The present invention provides imidazooxazole and imidazothiazole compounds and their synthesis. The compounds of the present invention are capable of inhibiting the activity of RAF kinase, such as B-RAF.sup.V600E. The compounds are useful for the treatment of cell proliferative disorders such as cancer.
Inventor(s): Lapierre; Jean-Marc (Pelham, NH), Namdev; Nivedita D. (Westford, MA), Ashwell; Mark A. (Carlisle, MA), France; Dennis S. (Carlisle, MA), Wu; Hui (Malden, MA), Hutchins; Patrick M. (Denver, CO), Tandon; Manish (Framingham, MA), Liu; Yanbin (Acton, MA), Link; Jeff S. (Londonderry, NH), Ali; Syed M. (North Andover, MA), Brassard; Chris J. (Somerville, MA), Nicewonger; Robb B. (Tyngsboro, MA), Filikov; Anton (Stoneham, MA), Carazza; Rebecca J. (Winchester, MA)
Assignee: ArQule, Inc. (Woburn, MA)
Application Number:11/785,163
Patent Claims:see list of patent claims

Details for Patent 7,501,430

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech Inc HERCEPTIN HYLECTA trastuzumab; hyaluronidase-oysk INJECTABLE;SUBCUTANEOUS 761106 001 2019-02-28   Start Trial ArQule, Inc. (Woburn, MA) 2026-04-17 RX search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 002 2017-06-22   Start Trial ArQule, Inc. (Woburn, MA) 2026-04-17 RX Orphan search
Genentech Inc RITUXAN HYCELA rituximab; hyaluronidase (human recombinant) SOLUTION;SUBCUTANEOUS 761064 001 2017-06-22   Start Trial ArQule, Inc. (Woburn, MA) 2026-04-17 RX Orphan search
Genentech AVASTIN bevacizumab VIAL; INTRAVENOUS 125085 002 2004-02-26   Start Trial ArQule, Inc. (Woburn, MA) 2026-04-17 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Merck
Harvard Business School
McKinsey
AstraZeneca
Colorcon
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.